All In Biotech

Drug Trial Radar · NCT01074944

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638

Last checked: Nov 19, 2026Latest source record: Feb 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

170

Actual

Start

Jun 2010

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Feb 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to evaluate the efficacy and safety of once daily (QD) versus twice daily (BID) dosing of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638). The secondary objective was to evaluate the pharmacokinetics (PK) of Genz-99067 when eliglustat tartrate (Genz-112638) was administered QD and BID in participants with Gaucher disease type 1 who had demonstrated clinical stability on BID dosing of eliglustat tartrate (Genz-112638).

Conditions

  • Gaucher Disease

Interventions

  • Eliglustat tartrateDrug

    Oral Capsule in 50 mg or 100 mg dosages

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PAP: Percentage of Participants Who Remained Stable for 52 Weeks During the PAPTime frame: PAP Baseline up to the end of PAP (Week 52)

Locations

46 sites in 17 countries. Site status is shown where the registry gives one.

  • University of California, San Diego Medical Center

    San Diego, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Emory University Medical Center

    Decatur, Georgia

  • Children's Memorial Hospital

    Chicago, Illinois

  • Mount Sinai Medical Center

    New York, New York

  • New York University School of Medicine

    New York, New York

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Utah

    Salt Lake City, Utah

  • O and O Alpan LLC

    Springfield, Virginia

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • Monash Medical Centre

    Clayton, VIC, Australia

  • Royal Perth Hospital

    Perth, WA, Australia

  • Medical University Vienna

    Vienna, Austria

  • Hospital das Clinicas da UFMG

    Belo Horizonte, Brazil

  • Cettro - Centro de Tratamento de Oncologia e Hematologia

    Brasília, Brazil

  • Hemocentro - UNICAMP

    Campinas, Brazil

  • Instituto Tropical de Medicina Reprodutiva e Menopausa - INTRO

    Cuiabá, Brazil

  • Hospital Universitario Walter Cantidio - HUWC

    Fortaleza, Brazil

  • Hemocentro de Ribeirão Preto Núcleo de Hemoterapia de Franca

    Franca, Brazil

  • Hemorio

    Rio de Janeiro, Brazil

  • Hospital de Clínicas da Universidade Federal do Parana

    São Paulo, Brazil

  • IGEIM - Institute of Genetic and Inborn Erros of Metabolism

    São Paulo, Brazil

  • Mount Sinai Hospital

    Toronto, Canada

  • Peking Union Medical College Hospital

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • Shanghai Xinhua Hospital Shanghai Xinhua Hospital

    Shanghai, China

  • Tianjin Hematonosis Hospital

    Tianjin, China

  • University Hospital Centre Zagreb

    Zagreb, Croatia

  • Hôpital Haut Lévêque

    Bordeaux, France

  • Hôpital Femme Mère Enfant Centre de référence des maladies Héréditaires du métabolisme

    Bron, France

  • General Hospital of Athens "G. Gennimatas"

    Athens, Greece

  • King Edward Memorial (KEM) Hospital

    Mumbai, India

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Jikei University Hospital

    Tokyo, Japan

  • Juntendo University Hospital

    Tokyo, Japan

  • Mie Chuou Medical Center

    Tsu, Mie, Japan

  • Academic Medical Center

    Amsterdam, Netherlands

  • Hospital de Santa Maria

    Lisbon, Portugal

  • Hospital do Divíno Espírito Santo

    Ponta Delgada - São Miguel - Açores, Portugal

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.